Table 3.
MDASI Assessment Results
| Symptom | Mean Rating | |
|---|---|---|
| Baseline | Follow-Up | |
| Pain | 1.36 | 1.71 |
| Fatigue | 2.64 | 4.46* |
| Nausea | 0.57 | 0.64 |
| Sleep disturbance | 1.50 | 1.62 |
| Distress | 3.64 | 3.08 |
| Shortness of breath | 1.14 | 1.36 |
| Memory problems | 2.71 | 3.54 |
| Loss of appetite | 2.14 | 3.08 |
| Drowsy | 1.79 | 2.08 |
| Dry mouth | 1.86 | 2.38 |
| Sadness | 2.43 | 3.00 |
| Vomiting | 2.71 | 2.93 |
| Numbness or tingling | 2.71 | 2.77 |
| Interferes with activity | 2.50 | 2.31 |
| Interferes with mood | 3.50 | 2.77 |
| Interferes with work | 2.00 | 2.38 |
| Interferes with relationships | 2.79 | 3.00 |
| Interferes with walking | 2.14 | 2.00 |
NOTE. MDASI data from 14 individuals were available for analysis. Symptoms rated from 7 to 10 are considered severe, whereas 4 to 7 are moderate. The Wilcoxon signed rank test was used to compare the baseline and follow-up symptom ratings. There was a significant increase in fatigue ratings on treatment, but this did not appear to interfere significantly with the patients’ ability to function.
Abbreviation: MDASI, M.D. Anderson Symptom Inventory.
*
P < .05.